BaiFan Biotech Files IPO Prospectus Highlighting Integrated Antibody CDMO Solutions Addressing Compliance and Cost Challenges

Since the second half of last year, impacted by centralized volume-based procurement and the COVID-19 pandemic, biotech companies—once highly favored by capital markets—have experienced a slowdown in primary market financing. In the secondary market, share prices of many biotech firms have corrected, and newly listed companies have frequently seen their stock prices fall below the IPO offering price.

Rather than focusing on innovative theories and technologies, investors are beginning to prioritize when products will be commercialized and when companies will achieve profitability. This also means that for biotech firms, product development is merely the first step toward success, with the subsequent commercialization phase proving even more critical.

Biotech Valuation Correction: Two Primary DriversThe correction in biotech valuations stems primarily from two factors. First, since the second half of last year, biotech companies have entered a harvest period, with products beginning to move toward commercialization. However, stepping outside their familiar realm of R&D into the fiercely competitive landscape of commercialization poses significant challenges for these firms’ survival and growth. The gap between commercial performance and expectations has led to a valuation correction.

Secondly, against the backdrop of healthcare insurance cost containment, there is significant uncertainty regarding the future profitability of Biotech companies’ product pipelines, which in turn affects their valuations.

“These biotech companies are all clients of CDMOs, and their current situation is making it increasingly challenging for CDMOs to secure orders. As the CDMO sector heats up, many new players have entered the market, further intensifying competition,” said Tan Kai, General Manager of Dragon Sail Pharmaceutical. “In this context, the core competitiveness of CDMOs lies in their ability to truly address the critical needs of biotech firms, alleviate their concerns, and help them successfully navigate the crucial test of commercialization.”

Dragon Sail Pharmaceutical, established in 2016, is a wholly-owned subsidiary of Guilin Sanjin Pharmaceutical Co., Ltd., dedicated to providing high-quality antibody drug CDMO/CMO services to industry peers.

Tan Kai, General Manager of Dragon Sail Pharmaceutical, previously served as Secretary to the Chairman of Guilin Sanjin and Director of the Institute of Biological Products. He possesses over 15 years of experience in strategic management, business development, finance, and human resources within publicly listed pharmaceutical companies.

Since its inception, Dragon Sail Pharmaceutical has recruited a team of seasoned industry experts. The core team members each possess over 15 years of experience in biopharmaceutical process R&D and production management. They have overseen the R&D, pilot-scale manufacturing, commercial production, and regulatory filing for more than ten antibody drug projects, with multiple projects achieving dual filings in both China and the United States. The team has accumulated extensive expertise in antibody production processes and quality control.

According to Tan Kai, Guilin Sanjin has been actively seeking a second growth engine since its initial public offering (IPO) in 2009. In 2010, China’s biopharmaceutical industry exhibited rapid growth, creating numerous market opportunities. Consequently, Guilin Sanjin designated biopharmaceuticals as its primary strategic direction and began building its innovative drug pipeline.

At that time, the domestic biopharmaceutical pipeline consisted predominantly of monoclonal antibody products, with significant shortcomings spanning R&D, manufacturing, and commercialization, resulting in a substantial technological gap between China and international markets. Around 2010, a large number of returning overseas scientists introduced advanced technologies that resolved challenges from the laboratory scale to small-scale and even pilot-scale trials. However, the transition from pilot-scale production to full-scale industrialization still faced intricate technical challenges.

“There is an urgent shortage of industrialization talent in China, and a gap exists in the transition from pilot-scale testing to full-scale industrial production. We aim to bridge this gap by providing the industry with truly compliant, large-scale commercial manufacturing services,” said Tan Kai.

In 2016, Guilin Sanjin strategically positioned itself in the antibody drug CDMO/CMO sector, aligning with its biological industry development. In 2020, Dragon Sail Pharmaceutical’s first domestic non-cross-contamination antibody manufacturing facility, located in the Lingang New Area of Shanghai, commenced operations. This production base complies with GMP standards in China, the United States, and Europe, and has successfully passed EU Qualified Person (QP) audits. The Phase I production capacity stands at 3 × 2,000 L, expandable to 6 × 2,000 L in Phase II. Its proprietary NONCROS® non-cross-contamination antibody production technology offers core advantages including regulatory compliance, rapid turnaround, high yield, and cost-effectiveness.

“The base can serve the Yangtze River Delta region and even the entire country, providing antibody drug CDMO/CMO services to peers, shortening new drug launch timelines, increasing effective production capacity, reducing drug costs, and improving patient access to biologics,” said Tan Kai.

Since its commencement of operations, Dragon Sail Pharmaceutical has established collaborations with more than 10 biopharmaceutical companies, offeringOne-Stop Services for Antibody Drugs: From Sequence to IND, Clinical Sample Production to BLA, and Commercial Manufacturing, accelerating corporate drug R&D, boosting the development of China’s biopharmaceutical industry, and providing patients with high-quality, affordable antibody therapies.

In recent years, the rapid development of China’s biopharmaceutical industry has created new market opportunities for the CDMO sector. The growing acceptance of industrial specialization among domestic biotech companies has also ushered in a favorable period of growth for the CDMO industry.

In Tan Kai’s view, the CDMO sector is a long-cycle, capital-intensive industry that requires sustained investment in R&D and manufacturing capabilities to maintain continuous competitiveness. Dragon Sail Pharmaceutical’s strategic focus on antibody drugs stems not only from its core team’s extensive experience in the industrialization of antibody therapeutics but also from its confidence in the future market potential of this segment.

The core logic of CDMOs lies in helping biotech companies reduce the risks and costs associated with early-stage drug development, shorten R&D cycles, and meet regulatory compliance requirements for product quality and safety.

Based on this, Dragon Sail PharmaceuticalTargeting Compliance and Cost Issues,Implement the concept of lean production,Focusing on Improving Efficiency and Quality, providing one-stop services from cell line development to commercial-scale production.

In terms of time control,The typical timeline from DNA to IND is 15 months., and can further shorten the R&D cycle based on customer and project requirements. During the commercialization phase, Dragon Sail Pharmaceutical'sNONCROS Non-Cross-Reactive Antibody Production Technology, which not only meets the compliance requirements for multi-product co-line production, maximizing production efficiency and cost-effectiveness, but also achieves a fully single-use process, thereby avoiding cross-contamination between products. All product-contact materials, from cell cryovials to the final vials containing the finished product, are replaceable.

Dragon Sail Pharmaceutical has also introduced imported equipment and software to achieve automated control in processes such as bulk drug substance and formulation manufacturing, thereby realizing industrial digitalization in the biopharmaceutical sector and significantly improving production efficiency. ThroughThe embedding of automation and informatization, adopting whole-process business management and control,Optimize the interaction and integration of key business processes, build an enterprise-wide, closed-loop management and control platform, and significantly enhance overall production quality control levels.

Furthermore, the production cost of antibodies is primarily comprised of culture media and consumables, accounting for 50%-60% of the final cost. Dragon Sail Pharmaceutical’s centralized bulk procurement keeps consumable prices at a low level, ensuring that customers’ production costs remain within a lower range and thereby enhancing the price competitiveness of their products.

To date, Dragon Sail Pharmaceutical has established collaborations with more than 10 biopharmaceutical companies.

“Many of our clients are scientists with deep expertise in their respective research fields. However, they often lack experience in GMP-compliant manufacturing. We are committed to leveraging our understanding of pharmaceuticals to allow scientists to focus on solving scientific problems, while Dragon Sail Pharmaceutical addresses compliance and commercialization challenges. This approach accelerates product time-to-market, enabling more patients to access higher-quality, lower-cost antibody therapies,” said Tan Kai.